At Kallyope, we are developing an industry-leading therapeutic platform based on our comprehensive understanding of gut-brain biology. Founded and headquartered in New York City, our cross-disciplinary team is integrating cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology and human genetics to provide an understanding of gut-brain biology that, when coupled with our deep drug discovery expertise, will lead to transformational therapeutics to improve human health.

Board of Directors

Amy Schulman

Polaris Partners

Adam Goulburn, Ph.D.

Lux Capital

Tim Kutzkey, Ph.D.

The Column Group

Nancy Thornberry

Chair, R&D

William Rieflin


Tom Maniatis, Ph.D.

Columbia University

Peter Hecht, Ph.D.


Jay Galeota

CEO & President

Strategic Advisors

Tony Evnin, Ph.D.

Strategic Advisor

Terry McGuire

Strategic Advisor

Josh Wolfe

Strategic Advisor